Pr Pierre-Louis Tharaux is a renowned MD, PhD, HDR, and Inserm Research Director (DR1), specializing in nephrology and vascular signaling. Founder and CMO of DETERA Therapeutics, he also presides over its Clinical Strategy Council.

Leading the Kidney and Vascular Signaling team at Inserm Unit 970, Professor Tharaux is an internationally recognized Key Opinion Leader in glomerular nephritis with complement involvement (GNC). His pioneering research has led to major advancements in understanding rare kidney diseases, published in top-tier scientific journals such as Nature Medicine (2011), JCI (2013), Kidney International (2014), and JASN (2016). He holds eight patents, including five focused on vascular disease-related kidney conditions, and was awarded an ERC Consolidator Grant (2013-2018) for his groundbreaking work.

His leadership extends to prestigious scientific committees, including the Kidney Foundation and the Rare Disease Foundation, where he contributes to advancing innovative treatments. Recognized for his achievements, he received the Inserm Research Award (2021), the Alnylam Rare Disease Award (2021), the Grand Prize of the Kidney Foundation (2019), and the Eloi Collery Prize (2013) from the French National Academy of Medicine. He has also secured two ERC grants (2012, 2018).

His expertise in glomerular kidney diseases and vascular pathologies is globally acknowledged. As Chair of the Translational Research Coordination Committee for the International Society of Glomerular Diseases (ISGD), he leads research efforts alongside renowned clinicians such as Prof. Alexandre Karras and Prof. Benjamin Terrier. His team collaborates actively with national and international networks, including the French Vasculitis Study Group (GFEV) and the European Vasculitis Study Group (EUVAS). He remains directly involved in clinical trials, driving forward cutting-edge therapeutic advancements.